DOCSLIB.ORG

Case Studies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

CHILDREN AND FAMILIES The RAND Corporation is a nonprofit institution that helps improve policy and EDUCATION AND THE ARTS decisionmaking through research and analysis. ENERGY AND ENVIRONMENT HEALTH AND HEALTH CARE This electronic document was made available from www.rand.org as a public INFRASTRUCTURE AND service of the RAND Corporation. TRANSPORTATION INTERNATIONAL AFFAIRS LAW AND BUSINESS NATIONAL SECURITY Skip all front matter: Jump to Page 16 POPULATION AND AGING PUBLIC SAFETY SCIENCE AND TECHNOLOGY Support RAND TERRORISM AND Browse Reports & Bookstore HOMELAND SECURITY Make a charitable contribution For More Information Visit RAND at www.rand.org Explore RAND Europe View document details Limited Electronic Distribution Rights This document and trademark(s) contained herein are protected by law as indicated in a notice appearing later in this work. This electronic representation of RAND intellectual property is provided for non-commercial use only. Unauthorized posting of RAND electronic documents to a non-RAND Web site is prohibited. RAND electronic documents are protected under copyright law. Permission is required from RAND to reproduce, or reuse in another form, any of our research documents for commercial use. For information on reprint and linking permissions, please see RAND Permissions. This report is part of the RAND Corporation research report series. RAND reports present research findings and objective analysis that address the challenges facing the public and private sectors. All RAND reports undergo rigorous peer review to ensure high standards for research quality and objectivity. EUROPE Mental Health Retrosight Case studies Alexandra Pollitt, Stephanie Diepeveen, Susan Guthrie, Molly Morgan Jones, Siobhán Ní Chonaill, Stuart S. Olmsted, Dana Schultz, Harold Alan Pincus, Jonathan Grant, Steven Wooding EUROPE Mental Health Retrosight Case studies Alexandra Pollitt, Stephanie Diepeveen, Susan Guthrie, Molly Morgan Jones, Siobhán Ní Chonaill, Stuart S. Olmsted, Dana Schultz, Harold Alan Pincus, Jonathan Grant, Steven Wooding Prepared for the Alliance of Mental Health Research Funders The project described in this report was supported in Canada by the Graham Boeckh Foundation, Alberta Innovates Health Solutions, and the Canadian Institutes of Health Research; in the UK by the National Institute for Health Research; and in the USA by the National Institute of Mental Health. RAND Europe is an independent, not-for-profit policy research organisation that aims to improve policy and decisionmaking for the public interest though research and analysis. RAND’s publications do not necessarily reflect the opinions of its research clients and sponsors. R® is a registered trademark © Copyright 2013 RAND Corporation Permission is given to duplicate this document for personal use only, as long as it is unaltered and complete. Copies may not be duplicated for commercial pur- poses. Unauthorized posting of RAND documents to a non-RAND website is prohibited. RAND documents are protected under copyright law. For informa- tion on reprint and linking permissions, please visit the RAND permissions page (www.rand.org/publications/permissions.html). RAND OFFICES SANTA MONICA, CA • WASHINGTON, DC PITTSBURGH, PA • NEW ORLEANS, LA • JACKSON, MS • BOSTON, MA DOHA, QA • CAMBRIDGE, UK • BRUSSELS, BE www.rand.org • www.rand.org/randeurope Preface Mental Health Retrosight was a three-year international project that aimed to investigate the translation and payback from mental health and neuroscience research, with a particular focus on schizophrenia. It looked at the development of research over a 20-year period in Canada, the USA and the UK. The project was supported in Canada by the Graham Boeckh Foundation, Alberta Innovates – Health Solutions, and the Canadian Institutes of Health Research; in the UK by the National Institute for Health Research; and in the USA by the National Institute of Mental Health. It was the first project funded through the Alliance of Mental Health Research Funders, a joint initiative between the Graham Boeckh Foundation and RAND Europe. The network was established as a ‘think tank without borders’ that would undertake research and analysis into mental health research funding. This report presents the full set of forward-tracing case studies. This is intended to complement the other reports associated with this study, which describe the findings and policy provocations, the methods and methodology, and the backward-tracing perspectives. RAND Europe is an independent not-for-profit policy research organisation that aims to improve policy and decision making in the public interest, through research and analysis. RAND Europe’s clients include European governments, institutions, NGOs and firms with a need for rigorous, independent, multidisciplinary analysis. This memo has been subject to RAND’s quality assurance process, but as an interim report on work in progress has not undergone full peer review. For more information about RAND Europe or this document, please contact: Alexandra Pollitt RAND Europe Westbrook Centre Milton Road Cambridge CB4 1YG United Kingdom Tel. +44 (1223) 353 329 [email protected] iii Contents Acknowledgements ................................................................................................... vii CHAPTER 1 Changes in striatal dopamine neurotransmission assessed with microdialysis following recovery from a bilateral 6-OHDA lesion: variation as a function of lesion size ........................................................ 1 CHAPTER 2 Synaptic modulation by dopamine of calcium currents in rat pars intermedia ............................................................................................ 15 CHAPTER 3 Differential distribution of GABAA receptor mRNAs in bovine cerebellum ............................................................................................ 31 CHAPTER 4 Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding ..................................................................... 55 CHAPTER 5 PET scanning and schizophrenia .......................................................... 77 CHAPTER 6 Organisation of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntingdon’s disease and schizophrenia ..................................................................... 99 CHAPTER 7 Auditory P300 in borderline personality disorder and schizophrenia ...................................................................................... 115 CHAPTER 8 Elevation of human brain D2 dopamine receptors in schizophrenia ...................................................................................... 137 CHAPTER 9 Expressed emotion research in London, UK, Chandigarh, India and Aarhus, Denmark ......................................................................... 165 CHAPTER 10 Northwick park study of outcomes following and characteristics prior to first schizophrenic episodes ............................ 193 CHAPTER 11 Low frontal glucose utilization in chronic schizophrenia: a replication study ................................................................................. 221 v Mental Health Retrosight RAND Europe CHAPTER 12 Using childhood home movies of adult schizophrenia patients to investigate the development of physical and behavioural abnormalities .................................................................. 235 CHAPTER 13 Verapamil in the treatment of chronic schizophrenia .................. 255 CHAPTER 14 The effects of neuroleptics on lateralisation in schizophrenic patients ............................................................................................... 273 CHAPTER 15 Specific and non-specific effects of educational intervention ....... 293 CHAPTER 16 Psychiatric morbidity of a long stay hospital population with chronic schizophrenia and implications for future community care .................................................................................................... 319 CHAPTER 17 Randomised controlled trial of an inpatient family intervention for schizophrenia and affective disorders: the importance of gender in outcome and treatment response .................. 343 CHAPTER 18 Treatment Strategies in Schizophrenia (TSS) .............................. 363 vi Acknowledgements We would like to acknowledge all the scientists who were willing to act as the participants for this study, particularly the interviewees for the 18 forward-tracing case studies. The study would clearly have been impossible without them. We would also like to thank our case study reviewers and our quality assurance reviewers, Tom Ling and Saba Hinrichs, who provided thoughtful, constructive and timely comments. vii CHAPTER 1 Changes in striatal dopamine neurotransmission assessed with microdialysis following recovery from a bilateral 6-OHDA lesion: variation as a function of lesion size This case study is based on the research that produced the paper: Castañeda, E., Whishaw, I.Q., & Robinson, T.E. (1990). Changes in striatal dopamine neurotransmission assessed with microdialysis following recovery from a bilateral 6-OHDA lesion: variation as a function of lesion size. Journal of Neuroscience, 10(6), 1847–1854. Information was gathered from an interview with the lead author, Edward Castañeda, an interview with co-author Ian Whishaw, and desk-based research. 1.1 Summary The target paper studied the effects of the destruction of nerve cells that produce dopamine on extra-cellular
Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • The Experiences of Emergency Medicine Physician Assistants Encountering Workplace Incivility

    The Experiences of Emergency Medicine Physician Assistants Encountering Workplace Incivility

    Resilience, Dysfunctional Behavior, and Sensemaking: The Experiences of Emergency Medicine Physician Assistants Encountering Workplace Incivility by James P. McGinnis B.S. as Physician Associate, May 1995, The University of Oklahoma MPAS in Emergency Medicine, May 2002, The University of Nebraska A Dissertation submitted to The Faculty of The Graduate School of Education and Human Development of The George Washington University in partial fulfillment of the requirements for the degree of Doctor of Education May 16, 2021 Dissertation directed by Shaista E. Khilji Professor of Human and Organizational Learning and International Affairs The Graduate School of Education and Human Development of The George Washington University certifies that James Patrick McGinnis, II has passed the Final Examination for the degree of Doctor of Education as of December 7, 2020. This is the final and approved form of the dissertation. Resilience, Dysfunctional Behavior, and Sensemaking: The Experiences of Emergency Medicine Physician Assistants Encountering Workplace Incivility James P. McGinnis Dissertation Research Committee: Shaista E. Khilji, Professor of Human and Organizational Learning, Dissertation Director Ellen F. Goldman, Professor of Human and Organizational Learning, Committee Member Neal E. Chalofsky, Associate Professor Emeritus, Committee Member ii Dedication To the unheralded Spartans of emergency medicine, themselves committed to the art of healing, who willingly stand in the breech between sickness and health, between life and death, and ultimately between chaos and order. iii Acknowledgement No person stands as an island. Despite our cries of independence, rugged individualism, and self-sufficiency, none of us attain success wholly upon our singular efforts. We are intimately intertwined with those who surround us and the relationships that we encounter throughout our lived experiences.
  • Appendix 13C: Clinical Evidence Study Characteristics Tables

    Appendix 13C: Clinical Evidence Study Characteristics Tables

    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
  • Resilience in Health and Illness

    Resilience in Health and Illness

    Psychiatria Danubina, 2020; Vol. 32, Suppl. 2, pp 226-232 Review © Medicinska naklada - Zagreb, Croatia RESILIENCE IN HEALTH AND ILLNESS 1,2 3 1,4 2 1 Romana Babiü , Mario Babiü , Pejana Rastoviü , Marina ûurlin , Josip Šimiü , 1 5 Kaja Mandiü & Katica Pavloviü 1Faculty of Health Studies, University of Mostar, Mostar, Bosnia & Herzegovina 2Department of Psychiatry, University Clinical Hospital Mostar, Mostar, Bosnia & Herzegovina 3Faculty of Science and Education University of Mostar, Mostar, Bosnia & Herzegovina 4Department of Surgery, University Clinical Hospital Mostar, Mostar, Bosnia & Herzegovina 5Department of Urology, University Clinical Hospital Mostar, Mostar, Bosnia & Herzegovina received: 11.4.2020; revised: 24.4.2020; accepted: 2.5.2020 SUMMARY Resilience is a relatively new concept that lacks clarity although it is increasingly used in everyday conversation and across various disciplines. The term was first introduced into psychology and psychiatry from technical sciences and afterwards thorough medicine and healthcare. It represents a complex set of various protective and salutogenic factors and process important for understanding health and illness, and treatment and healing processes. It is defined as a protective factor that makes an individual more resilient to adverse events that lead to positive developmental outcomes. Resilience is a positive adaptation after stressful situations and it represents mechanisms of coping and rising above difficult experiences, i.e., the capacity of a person to successfully adapt to change, resist the negative impact of stressors and avoid occurrence of significant dysfunctions. It represents the ability to return to the previous, so-called "normal" or healthy condition after trauma, accident, tragedy, or illness. In other words, resilience refers to the ability to cope with difficult, stressful and traumatic situations while maintaining or restoring normal functioning.
  • How Educators Can Nurture Resilience in High-Risk Children and Their Families

    How Educators Can Nurture Resilience in High-Risk Children and Their Families

    HOW EDUCATORS CAN NURTURE RESILIENCE IN HIGH-RISK CHILDREN AND THEIR FAMILIES Donald Meichenbaum, Ph.D. Distinguished Professor Emeritus, University of Waterloo Waterloo, Ontario, Canada and Research Director of The Melissa Institute for Violence Prevention and Treatment Miami, Florida www.melissainstitute.org and www.TeachSafeSchools.org University of Waterloo Contact: (Oct. – May) Department of Psychology Donald Meichenbaum Waterloo, Ontario 215 Sand Key Estates Drive Canada N2L 3G1 Clearwater, FL 33767 Phone: (519) 885-1211 ext. 2551 Email: [email protected] Meichenbaum 2 WAYS TO BOLSTER RESILIENCE IN CHILDREN In the aftermath of both natural disasters (e.g., hurricanes, tornadoes, earthquakes), and man-made trauma (e.g., terrorist attacks), educators are confronted with the challenging question of how to help their students and families cope and recover from stressful events. There are lessons to be learned from those children and families who evidence “resilience” in the face of stressful events. To introduce this topic, consider the following question: “Are there any children in your school who, when you first heard of their backgrounds, you had a great deal of concern about them? Now when you see them in the hall, you have a sense of pride that they are part of your school. These children may cause you to wonder, ‘How can that be?’” This question has been posed to educators by one of the founders of the research on resilience in children, Norman Garmezy. It reflects the increasing interest in how children who grow up in challenging circumstances and who have experienced traumatic events “make it” against the odds.
  • Measuring Post-Secondary Student Resilience Through the Child & Youth Resilience Measure and the Brief Resilience Scale

    Measuring Post-Secondary Student Resilience Through the Child & Youth Resilience Measure and the Brief Resilience Scale

    Measuring Post-Secondary Student Resilience Through the Child & Youth Resilience Measure and the Brief Resilience Scale by Hany Soliman A thesis submitted in conformity with the requirements for the degree of Master of Arts in Higher Education Graduate Department of Leadership, Higher and Adult Education The Ontario Institute for Studies in Education University of Toronto © Copyright by Hany Soliman 2017 Measuring Post-Secondary Student Resilience Through the Child & Youth Resilience Measure and the Brief Resilience Scale Master of Arts 2017 Hany Soliman Department of Leadership, Higher and Adult Education University of Toronto Abstract This thesis examines how the Child & Youth Resilience Measure (CYRM-12) and the Brief Resilience Scale (BRS) measure post-secondary student resilience as viewed by the University of Toronto in Toronto, Canada, which breaks down resilience into competence domains and adaptive resources. Cognitive interviews were conducted to assess item comprehension, with some items causing confusion with students. The two scales were administered in a survey instrument for a sample of 87 second- and third-year undergraduate students. Internal consistency reliability is high for both the CYRM-12 (Cronbach’s alpha = .82) and the BRS (Cronbach’s alpha = .83). Exploratory Factor Analysis yielded a 3-factor solution for the CYRM-12 representing family, friends and community, and a 1-factor solution for the BRS representing the ability to recover from stress. Scores from both scales indicate strengths in motivation and achievement orientation with more variability in familial relations and community belongingness. Limitations include a low response rate. ii Acknowledgments I am both grateful for and humbled by this opportunity to conduct a master’s thesis project.
  • Formulary (List of Covered Drugs)

    Formulary (List of Covered Drugs)

    3ODQ<HDU 202 Formulary (List of Covered Drugs) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THE FOLLOWING PLAN: $0 Cost Share AI/AN HMO Minimum Coverage HMO Silver 70 HMO Active Choice PPO Silver Opal 25 Gold HMO Silver 70 OFF Exchange HMO Amber 50 HMO Silver Opal 50 Silver HMO Silver 73 HMO Bronze 60 HDHP HMO Platinum 90 HMO Silver 87 HMO Bronze 60 HMO Ruby 10 Platinum HMO Silver 94 HMO Gold 80 HMO Ruby 20 Platinum HMO Jade 15 HMO Ruby 40 Platinum HMO This formulary was last updated on8//20. This formulary is VXEMHFWto change and all previous versions of the formulary no longer apply. For more recent information or other questions, please contact Chinese Community Health Plan Member Services at 1-888-775-7888 or, for TTY users, 1-877-681-8898, seven days a week from 8:00 a.m. to 8:00 p.m., or visit www.cchphealthplan.com/family-member -,-ϭ -,-ϭ"&* !#" + 5 5 ),-$+" %(%'.')/"+#" %&/"+ -%/"$)% "%&/"+ *& )&! %&/"+ 0 $(#" '"+ %&/"+ *& %&/"+ %&/"+ +)(2" &-%(.' %&/"+ +)(2" .1&-%(.' %&/"+ )&! .1&-%(.' !" .1&-%(.' dŚŝƐĨŽƌŵƵůĂƌLJǁĂƐůĂƐƚƵƉĚĂƚĞĚ8ͬϭͬϮϬϮϭ͘dŚŝƐĨŽƌŵƵůĂƌLJŝƐƐƵďũĞĐƚƚŽ ĐŚĂŶŐĞĂŶĚĂůůƉƌĞǀŝŽƵƐǀĞƌƐŝŽŶƐŽĨƚŚĞĨŽƌŵƵůĂƌLJŶŽůŽŶŐĞƌĂƉƉůLJ͘&ŽƌŵŽƌĞ ƌĞĐĞŶƚŝŶĨŽƌŵĂƚŝŽŶŽƌŽƚŚĞƌƋƵĞƐƚŝŽŶƐ͕ƉůĞĂƐĞĐŽŶƚĂĐƚŚŝŶĞƐĞŽŵŵƵŶŝƚLJ ,ĞĂůƚŚWůĂŶDĞŵďĞƌ^ĞƌǀŝĐĞƐĂƚϭͲϴϴϴͲϳϳϱͲϳϴϴϴŽƌ͕ĨŽƌddzƵƐĞƌƐ͕ ϭͲϴϳϳͲϲϴϭͲϴϴϵϴ͕ƐĞǀĞŶĚĂLJƐĂǁĞĞŬĨƌŽŵϴ͗ϬϬĂ͘ŵ͘ƚŽϴ͗ϬϬƉ͘ŵ͕͘ŽƌǀŝƐŝƚ ǁǁǁ͘ĐĐŚƉŚĞĂůƚŚƉůĂŶ͘ĐŽŵͬĨĂŵŝůLJͲŵĞŵďĞƌ !! %+)&,+ &%+&+&)$,#)0),# *+666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666I % + &%*6666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666I
  • Antipsychotics (Part-4) FLUOROBUTYROPHENONES

    Antipsychotics (Part-4) FLUOROBUTYROPHENONES

    Antipsychotics (Part-4) FLUOROBUTYROPHENONES The fluorobutyrophenones belong to a much-studied class of compounds, with many compounds possessing high antipsychotic activity. They were obtained by structure variation of the analgesic drug meperidine by substitution of the N-methyl by butyrophenone moiety to produce the butyrophenone analogue which has similar activity as chlorpromazine. COOC2H5 N H3C Meperidine COOC2H5 N O Butyrophenone analog The structural requirements for antipsychotic activity in the group are well worked out. General features are expressed in the following structure. F AR Y O N • Optimal activity is seen when with an aromatic with p-fluoro substituent • When CO is attached with p-fluoroaryl gives optimal activity is seen, although other groups, C(H)OH and aryl, also give good activity. • When 3 carbons distance separates the CO from cyclic N gives optimal activity. • The aliphatic amino nitrogen is required, and highest activity is seen when it is incorporated into a cyclic form. • AR is an aromatic ring and is needed. It should be attached directly to the 4-position or occasionally separated from it by one intervening atom. • The Y group can vary and assist activity. An example is the hydroxyl group of haloperidol. The empirical SARs suggest that the 4-aryl piperidino moiety is superimposable on the 2-- phenylethylamino moiety of dopamine and, accordingly, could promote affinity for D2 receptors. The long N-alkyl substituent could help promote affinity and produce antagonistic activity. Some members of the class are extremely potent antipsychotic agents and D2 receptor antagonists. The EPS are extremely marked in some members of this class, which may, in part, be due to a potent DA block in the striatum and almost no compensatory striatal anticholinergic block.
  • Monoamine Depletion in Psychiatric and Healthy Populations

    Monoamine Depletion in Psychiatric and Healthy Populations

    Molecular Psychiatry (2003) 8, 951–973 & 2003 Nature Publishing Group All rights reserved 1359-4184/03 $25.00 www.nature.com/mp FEATURE REVIEW Monoamine depletion in psychiatric and healthy populations: review L Booij1, AJW Van der Does1,2 and WJ Riedel3,4,5 1Department of Psychology, Leiden University, Leiden 2333 AK, The Netherlands; 2Department of Psychiatry, Leiden University, Leiden 2333 AK, The Netherlands; 3GlaxoSmithKline, Translational Medicine & Technology, Cambridge, UK; 4Department of Psychiatry, University of Cambridge, UK; 5Faculty of Psychology, Maastricht University, The Netherlands A number of techniques temporarily lower the functioning of monoamines: acute tryptophan depletion (ATD), alpha-methyl-para-tyrosine (AMPT) and acute phenylalanine/tyrosine deple- tion (APTD). This paper reviews the results of monoamine depletion studies in humans for the period 1966 until December 2002. The evidence suggests that all three interventions are specific, in terms of their short-term effects on one or two neurotransmitter systems, rather than on brain protein metabolism in general. The AMPT procedure is somewhat less specific, affecting both the dopamine and norepinephrine systems. The behavioral effects of ATD and AMPT are remarkably similar. Neither procedure has an immediate effect on the symptoms of depressed patients; however, both induce transient depressive symptoms in some remitted depressed patients. The magnitude of the effects, response rate and quality of response are also comparable. APTD has not been studied in recovered major depressive patients. Despite the similarities, the effects are distinctive in that ATD affects a subgroup of recently remitted patients treated with serotonergic medications, whereas AMPT affects recently remitted patients treated with noradrenergic medications.
  • The Effects of Clonidine and Idazoxan on Cerebral Blood Flow in Rats Studied by Arterial Spin Labeling Magnetic Resonance Perfusion Imaging

    The Effects of Clonidine and Idazoxan on Cerebral Blood Flow in Rats Studied by Arterial Spin Labeling Magnetic Resonance Perfusion Imaging

    The Effects of Clonidine and Idazoxan on Cerebral Blood Flow in Rats Studied by Arterial Spin Labeling Magnetic Resonance Perfusion Imaging X. Du1, H. Lei1 1State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, Wuhan Institute of Physics & Mathematics, Chinese Academy of Sciences, Wuhan, Hubei, China, People's Republic of Introduction Agonists of α2-adrenoceptors are known to produce many central and peripheral effects. For example, xylazine, a selective α2-adrenoceptors agonist, has been shown to cause region-dependent CBF decreases in rat [1]. Clonidine, an agonist for both α2-adrenergic receptor and imidazoline receptor, is a widely used drug for treating hypertension. Its effect on CBF, however, is not well understood. In this study, continuous arterial labeling (CASL) MR perfusion imaging was used to investigate the effects of clonidine and idazoxan, an antagonist for α2-adrenergic and imidazoline receptors, on CBF in rats. Materials and Methods Twelve male Sprague-Dawley rats, weighting 250-320 g, were used. After intubation, the rats were anesthetized by 1.0-1.5% isoflurane in a 70:30 N2O/O2 gas mixture. For each rat, bilateral femoral arteries and the right femoral vein were catheterized for monitoring blood gases and blood pressure, and for delivering drugs. Rectal temperature was maintained at 37.0-37.5 oC using a warm water pad. After measuring baseline CBF, the rats were divided into two groups. In the first group (n=7), clonidine (10 µg/kg, i.v.) was injected first, followed by idazoxan injection (300 µg/kg, i.v.) at 30 minutes later. Perfusion maps were obtained after administration of each drug.
  • Patterns of Antipsychotic Prescription to Patients with Schizophrenia in Korea: Results from the Health Insurance Review & Assessment Service-National Patient Sample

    Patterns of Antipsychotic Prescription to Patients with Schizophrenia in Korea: Results from the Health Insurance Review & Assessment Service-National Patient Sample

    ORIGINAL ARTICLE Psychiatry & Psychology http://dx.doi.org/10.3346/jkms.2014.29.5.719 • J Korean Med Sci 2014; 29: 719-728 Patterns of Antipsychotic Prescription to Patients with Schizophrenia in Korea: Results from the Health Insurance Review & Assessment Service-National Patient Sample Seon-Cheol Park,1,2 Myung-Soo Lee,3 This study aimed to analyze the patterns of antipsychotic prescription to patients with Seung-Gul Kang,4 and Seung-Hwan Lee5 schizophrenia in Korea. Using the Health Insurance Review & Assessment Service-National Patients Sample (HIRA-NPS), which was a stratified sampling from the entire population 1 Department of Psychiatry, Yong-In Mental Hospital, under the Korean national health security system (2009), descriptive statistics for the Yongin; 2Institute of Mental Health, Hanyang University, Seoul; 3Seoul Mental Health Center & patterns of the monopharmacy and polypharmacy, neuropsychiatric co-medications, and Seoul Suicide Prevention Center, Seoul; 4Department prescribed individual antipsychotic for patients with schizophrenia were performed. of Psychiatry, Gachon University, School of Comparisons of socioeconomic and clinical factors were performed among patients 5 Medicine, Incheon; Department of Psychiatry, Inje prescribed only with first- and second-generation antipsychotics. Of 126,961 patients with University Ilsan Paik Hospital, Goyang, Korea schizophrenia (age 18–80 yr), 13,369 were prescribed with antipsychotic monopharmacy Received: 19 December 2013 and the rest 113,592 with polypharmacy. Two or more antipsychotics
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.